AMGN

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 62.0/100

📰 Latest News

Amgen Inc. pioneers innovative human therapeutics, leveraging its expertise in biotechnology to address critical unmet needs in oncology, cardiovascular disease, and bone health, offering investors a stable dividend yield of 2.48% and a proven track record of profitability with a 21.0% profit margin.

About AMGN

Amgen Inc. is a leading biotechnology company focused on discovering, developing, and delivering innovative human therapeutics. With a diverse portfolio and a global reach, Amgen addresses critical unmet needs in areas like oncology, cardiovascular disease, and bone health.

Amgen Inc. Company Overview

Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. The company's evolution has been marked by a focus on addressing serious illnesses across a range of therapeutic areas, including inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Amgen's diverse product portfolio includes established brands like Enbrel for inflammatory conditions, Neulasta for preventing infections in cancer patients, and Prolia for treating osteoporosis. Newer products such as Repatha, which reduces the risk of cardiovascular events, and Otezla, used in the treatment of psoriasis and psoriatic arthritis, demonstrate Amgen's commitment to innovation. Amgen distributes its products globally through pharmaceutical wholesale distributors and direct-to-consumer channels, serving healthcare providers such as physicians, dialysis centers, hospitals, and pharmacies. Strategic collaborations with companies like Novartis, UCB, and BeiGene, Ltd. enhance Amgen's research and development capabilities and expand its market reach. With a market capitalization of $206.95 billion, Amgen maintains a strong market position, driven by its robust pipeline and established presence in key therapeutic areas.

Investment Thesis

Amgen presents a compelling investment opportunity due to its established market position, diverse product portfolio, and commitment to innovation. With a P/E ratio of 26.86 and a healthy profit margin of 21.0%, Amgen demonstrates financial stability and profitability. Key value drivers include continued growth in sales of key products like Repatha and Otezla, as well as successful development and commercialization of pipeline assets. The company's dividend yield of 2.48% provides an attractive income stream for investors. Upcoming catalysts include potential regulatory approvals for new therapies and expansion of existing product indications. Amgen's strategic collaborations and acquisitions further enhance its growth prospects, making it a solid long-term investment.

Key Financial Highlights

• Market Cap of $206.95B reflects Amgen's significant presence in the biotechnology industry.
• P/E ratio of 26.86 indicates a reasonable valuation compared to its earnings.
• Profit Margin of 21.0% demonstrates strong profitability and operational efficiency.
• Gross Margin of 70.5% showcases Amgen's ability to maintain high pricing power and manage production costs effectively.
• Dividend Yield of 2.48% provides a steady income stream for investors, highlighting Amgen's commitment to shareholder returns.

Industry Context

Amgen operates in the dynamic and competitive drug manufacturing industry, characterized by rapid innovation and evolving regulatory landscapes. The global pharmaceutical market is projected to reach trillions of dollars by 2026, driven by increasing healthcare expenditure and aging populations. Amgen competes with major pharmaceutical companies like Bristol-Myers Squibb (BMY), Boston Scientific (BSX), Danaher (DHR), Gilead Sciences (GILD), and GSK (GSK), all vying for market share in key therapeutic areas. Amgen differentiates itself through its focus on biologics and its expertise in complex manufacturing processes. The industry is also witnessing a rise in biosimilars, posing both a challenge and an opportunity for Amgen.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expansion of Otezla's Indications: Otezla, currently approved for psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease, has the potential for expansion into new indications such as atopic dermatitis. The atopic dermatitis market is projected to reach billions of dollars by 2028. Successful clinical trials and regulatory approvals for new indications could significantly boost Otezla's revenue and Amgen's overall growth.
• Development and Commercialization of KHK4083: Amgen's collaboration with Kyowa Kirin Co., Ltd. to develop and commercialize KHK4083, a Phase 3-ready anti-OX40 antibody for atopic dermatitis and other autoimmune diseases, represents a significant growth opportunity. The autoimmune disease market is a multi-billion dollar market, and KHK4083 has the potential to become a blockbuster drug, driving substantial revenue for Amgen.
• Oncology Pipeline Advancement: Amgen's oncology pipeline includes several promising candidates targeting various cancers. Successful clinical trials and regulatory approvals for these candidates could significantly expand Amgen's presence in the oncology market, which is one of the largest and fastest-growing segments of the pharmaceutical industry. The collaboration with Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer is one such opportunity.
• Biosimilar Development and Commercialization: Amgen is actively developing and commercializing biosimilars of blockbuster drugs, offering a cost-effective alternative to branded biologics. The biosimilar market is experiencing rapid growth as patents for many biologics expire. Amgen's expertise in biologics manufacturing gives it a competitive advantage in this market, allowing it to capture significant market share and drive revenue growth.
• Strategic Acquisitions and Partnerships: Amgen has a history of strategic acquisitions and partnerships to expand its product portfolio and pipeline. Continued strategic deals, such as the research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc., can provide access to innovative technologies and therapies, driving long-term growth. Identifying and acquiring promising biotech companies or assets can significantly enhance Amgen's competitive position and future prospects.

Competitive Advantages

• Patented drug formulations provide market exclusivity.
• Expertise in complex biologics manufacturing creates a barrier to entry.
• Established brand reputation and strong relationships with healthcare providers.
• Robust pipeline of new drug candidates ensures future growth.
• Economies of scale in manufacturing and distribution.

Strengths

• Strong product portfolio with established brands.
• Robust pipeline of new drug candidates.
• Expertise in biologics manufacturing.
• Global distribution network.

Weaknesses

• Reliance on a few key products for revenue.
• Exposure to biosimilar competition.
• High research and development costs.
• Dependence on regulatory approvals.

Opportunities

• Expansion into new therapeutic areas.
• Strategic acquisitions and partnerships.
• Growth in emerging markets.
• Development of innovative drug delivery systems.

Threats

• Patent expirations and generic competition.
• Pricing pressures from healthcare payers.
• Unfavorable regulatory changes.
• Clinical trial failures.

What AMGN Does

• Discovers novel human therapeutics.
• Develops innovative medicines for serious illnesses.
• Manufactures complex biologic products.
• Delivers therapies to healthcare providers and patients worldwide.
• Focuses on therapeutic areas including oncology, cardiovascular disease, and bone health.
• Engages in research and development to advance medical science.
• Commercializes and markets its products globally.

Business Model

• Develops and patents novel biologic drugs.
• Manufactures and sells these drugs to healthcare providers and patients.
• Generates revenue through direct sales and distribution agreements.
• Reinvests profits into research and development to create new products.

Key Customers

• Physicians and their clinics.
• Hospitals and medical centers.
• Dialysis centers.
• Pharmacies.
• Patients requiring specialized therapies.

Competitors

• Bristol-Myers Squibb (BMY): Focuses on oncology, hematology, immunology, and cardiovascular diseases.
• Boston Scientific (BSX): Develops medical devices and technologies.
• Danaher (DHR): Offers a broad range of products and services in life sciences, diagnostics, and environmental and applied solutions.
• Gilead Sciences (GILD): Focuses on antiviral drugs for HIV, hepatitis, and influenza.
• GSK (GSK): Global healthcare company with a focus on pharmaceuticals, vaccines, and consumer healthcare.

Catalysts

• Upcoming: Regulatory approvals for new drug candidates in the oncology and inflammation pipelines.
• Ongoing: Continued growth in sales of key products like Repatha and Otezla.
• Ongoing: Expansion of existing product indications through clinical trials.
• Upcoming: Data readouts from ongoing clinical trials for pipeline assets.
• Ongoing: Strategic collaborations and acquisitions to expand the product portfolio.

Risks

• Potential: Patent expirations on key products leading to generic competition.
• Ongoing: Pricing pressures from healthcare payers and government regulations.
• Potential: Clinical trial failures for pipeline assets.
• Ongoing: Competition from biosimilars.
• Potential: Product liability claims and litigation.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Drug Manufacturers - General

Browse More

Next Steps